Business Wire
15 Jul 2026, 07:30 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Alnylam is developing mivelsiran, an investigational RNAi therapeutic targeting amyloid precursor protein (APP) for Alzheimer's disease. — Expansion into the high-addressable Alzheimer's market with a novel mechanism (RNAi) represents a significant long-term growth catalyst.
+0.40Alnylam presented neuroscience portfolio advances at the Alzheimer's Association International Conference (AAIC) 2026. — Scientific conference presentations signal pipeline progress but lack the definitive data or regulatory milestones required for major price movements.
+0.20Which stocks this story touches
The company shared scientific advances in its neuroscience portfolio and the potential of its RNAi therapeutics.
Continue reading
6 related stories
Top 3 movers · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Benzinga
15h ago
